Funding
Seed · Biotech

GelMEDIX raises $13m seed round for retinal therapies

Safar Partners, HTL Biotechnology and angel groups participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

GelMEDIX raised $13 million in seed financing on February 17. Participants included Safar Partners, HTL Biotechnology, Beacon Angels, TiE Boston Angels and Boston Harbor Angels. The company develops regenerative therapies targeting damaged retinal cells.

Funding history

Seed · This round$13M

Sources

  1. GelMEDIXprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related